One-step engineering of allogeneic cell therapies with Pin-point base editing platform and an AI-engineered Cas enzyme

In this scientific poster, we describe a one-step process to engineer allogeneic cell immunotherapies using the Pin-point™ base editing platform and an AI-engineered CRISPR-Cas enzyme.

You will learn how:

• Aptamer-dependent recruitment of the deaminase supports site-specific transgene knock-in in parallel with multi-gene base editing in a single intervention
• Reduced cytotoxicity and reduced spurious genomic rearrangements make Pin-point platform a safer and more efficient tool for multiplexed cell engineering.
• The modularity of the Pin-point platform enabled the use of AI-engineered OpenCRISPR-1 for efficient multiplex KO and transgene KI.

Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.